SL Science Holding Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About SL Science
Biological Products, (No Diagnostic Substances), SIC 2836
SL Science Holding Limited is a biomedical holding company focused on creating cellular and gene therapies for immuno-oncology and tissue regeneration through its operating subsidiary, SL Bio. Its primary therapeutic candidates include CD-19 Armed-T therapy for hematologic cancers and gamma delta T-cell platforms designed to target pancreatic and brain cancers. The company also maintains legacy product lines in exosome-based cosmetics and plant supplements while partnering with biopharmaceutical organizations to advance its pre-clinical oncology pipelines toward clinical trials.
The company operates its principal executive office in Taipei, Taiwan, and maintains an incorporated registered office in the Cayman Islands. Its research and collaborative licensing arrangements extend across Taiwan and the United States. SL Science relies on contract development and manufacturing organization facilities in the United States to produce qualified cellular materials for its therapeutic pipeline development.
Summary of the business section of SL Science's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SL Science Holding Ltd
- Founded
- 2025
- Headquarters
- Taipei City, Taiwan
- Address
- 11/F, No. 479 Chongyang Road, Nangang District 115010
- Phone
- 886-2-26516826
- Website
- slbtgroup.com
- Employees
- 20, Jun 12, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- E9
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- SLBT
- Exchange
- Nasdaq
- IPO date
- Feb 5, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2070534
- CUSIP
- G8191L116
- ISIN
- USG8191L1165
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ching-Dong Wang | Chief Executive Officer, Director | 333,832,129 |
| Ethan Shen PhD | Chief Technology Officer, Director | – |
| Lok Sang Leung | Chief Financial Officer | – |
| Qian Xu | Director | 20,000 |
| John Conrad General | Director | – |
| Mingche Liu | Director | – |
| Kwo-Liang Chen | Director | – |
| Joseph Levinson | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 11, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 18, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |